...
首页> 外文期刊>Journal of dual diagnosis >Validation of Addiction Severity Index (ASI) for Assessment of Psychiatric Comorbidity in Multi-Site Randomized Controlled Trials
【24h】

Validation of Addiction Severity Index (ASI) for Assessment of Psychiatric Comorbidity in Multi-Site Randomized Controlled Trials

机译:验证成瘾严重性指数(ASI),用于评估多位点随机对照试验中的精神疗法合并症

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: This study aimed to assess the validity of the psychiatric problems subscale of the Addiction Severity Index (ASI-psych) to ascertain psychiatric comorbidity among individuals participating in randomized controlled trials (RCTs) of substance use disorder (SUD) treatments. Methods: The ASI-psych score among 1,660 RCT participants of National Institute of Drug Abuse Clinical Trials Network studies was compared against diagnosis of any serious mental disorder based on the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (SCID) or Mini-International Neuropsychiatric Interview (MINI). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) for detecting any serious mental disorders were estimated by the receiver operating characteristic (ROC) analysis. Results: Based on the overall sample, the AUC score for any serious mental disorder was 0.72 (95% confidence interval [CI], [0.69, 0.75]) with the optimal ASI-psych score of 24.6. There was no statistically significant difference in AUCs based on the SCID and MINI (chi(2) = 0.05, p = .82) or by target drugs of RCTs (chi(2) =1.33, p = .72). Conclusions: Results support the utility of the ASI in screening for psychiatric comorbidity among patients receiving SUD treatments in RCT settings.
机译:目的:本研究旨在评估成瘾严重程度指数(ASI-FESC)的精神病问题副船舶的有效性,以确定参与物质使用障碍(SUD)治疗的随机对照试验(RCT)的个体之间的精神疾病合并症。方法:在国家药物滥用临床试验网络研究所的1,660名RCT参与者中的ASI-PESC分数与诊断和统计手册诊断和统计手册(SCID)的结构化临床面试进行了诊断,抑制了任何严重的精神障碍或迷你国际神经精神科访谈(迷你)。通过接收器操作特征(ROC)分析估计了用于检测任何严重精神障碍的曲线(AUC)下的敏感性,特异性,阳性预测值(PPV),负预测值(NPV)和面积。结果:根据整体样品,任何严重精神障碍的AUC分数为0.72(置信区间95%,[0.69,0.75]),最佳ASI-PEST分数为24.6分。基于SCID和MINI(CHI(2)= 0.05,p = .82)或RCT的目标药物没有统计学上显着差异(CHI(2)= 1.33,p = .72)。结论:结果支持ASI在RCT环境中抑制患者的精神病合并筛查中的效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号